

Titolo: Real-world course in metastatic breast cancer: therapeutic algorithms beyond guidelines in clinical choices and decisions

Sede e data: Hotel NH Collection Touring, Milano, 15 dicembre 2026

Responsabile Scientifico: Claudio Vernieri

Provider ECM: Symposia Organizzazione Congressi Srl - ID 486

N. Accredimento ECM: 496561

Ore formative: 7

Crediti ECM: 7

Obiettivo formativo: Linee Guida – protocolli - procedure

Destinatari dell'iniziativa: N. 70 Medici Chirurghi specialisti in Oncologia, Anatomia Patologica

Programma Scientifico

08.45 *Welcome Coffee and Registration*

09.00 Obiettivi del Corso *Claudio Vernieri*

09.30 **Opening Lecture:**

Evolution of treatments and priorities in metastatic breast cancer (mBC): towards the final cure?
Giuseppe Curigliano

Guidelines vs. clinical practice: the factors that guide the choice

Moderatore: *Claudio Vernieri*

10.00 International guidelines in metastatic breast cancer: where tumor-related factors are prominent
Matteo Lambertini

10.25 The evolving role of tumor genomics and biology in clinical decision making *Giancarlo Pruneri*

10.50 Clinical practice: when clinical factors make the difference *Giampaolo Bianchini*

11.15 Discussion

11.35 *Coffee Break*

Guidelines vs. clinical practice: is the real-world coherent with recommendations?

Moderatori: *Carmen Criscitiello, Maria Vittoria Dieci*

11.50 HR+/HER2- mBC *Claudio Vernieri*

12.10 HER2+ mBC *Carmen Criscitiello*

12.30 mTNBC *Maria Vittoria Dieci*

12.50 Discussion

13.10 *Buffet Lunch*



Sistema Qualità **ISO 9001**
Progettazione e Erogazione ECM

Emerging areas for clinical decision making and their impact on clinical practice

Moderatori: *Claudio Vernieri, Gabriella Pravettoni*

- 14.00 The voice of patients: expectations, requests and priorities *Laura Marziali*
- 14.20 Taking into account patient needs in designing and evaluating clinical trials *Dario Trapani*
- 14.40 Taking into account patient preferences in clinical practice: a pragmatic approach to the problem
Gabriella Pravettoni
- 15.00 Discussion

- 15.30 Multimodal algorithms to personalize treatment choices in metastatic breast cancer *Leonardo Provenzano*
- 15.50 Looking at the future: how to take into account all these variables in the most effective manner in the clinical practice? *Alberto Zambelli*
- 16.10 Discussion

- 16.35 Conclusions *Claudio Vernieri*
- 17.05 End of the course

RAZIONALE

Impressive therapeutic progress has been made in the treatment of patients with metastatic breast cancer in recent years. In particular, the advent of cyclin-dependent kinase inhibitors, novel targeted therapies and, more recently, highly effective antibody-drug conjugates resulted in a dramatic increase in tumor responses and in higher survival expectancy across all breast cancer biologies.

However, clinical trials investigating novel treatments for metastatic breast cancer typically enroll patients that are selected on the basis of strict clinical and biological criteria, such as better performance status, higher motivation to receive systemic therapies, absence of severe comorbidities and more controlled concomitant pharmacological treatments; in addition, patients enrolled in clinical trials are clinically and radiologically re-evaluated according to tighter schedules, thus allowing a more rigorous and timely assessment of tumor control and of treatment toxicities. By contrast, patients treated in clinical practice are much more heterogeneous in terms of clinical and biological characteristics, as well as in terms of tumor re-evaluation schedules.

For these reasons, the translation of novel treatments for metastatic breast cancer in broad and heterogeneous patient populations, as well as the assessment of safety, feasibility and effectiveness of these treatments in clinical practice is a challenging issue, which requires dedicated studies and discussions to understand how these novel treatments actually impact on patient survival, quality of life and global well-being.

This course, which puts together oncologists, pathologists, psychologists and advocates who are experts in the management of patients with metastatic breast cancer, aims to discuss: 1) the available evidence regarding the effectiveness of novel treatments for metastatic breast cancer in clinical practice; 2) the impact of these novel treatments on patient survival, quality of life and global well-being on the basis of published studies and individual clinical experience; c) how patients perceive the advent of more and more effective systemic therapies in terms of their impact on several domains related to patient well-being, including not only physical, emotional and cognitive well-being, but also type and quality of social and familiar interactions and impact on job activities and career.



Sistema Qualità **ISO 9001**
Progettazione e Erogazione ECM

ACRONIMI

mBC Metastatic Breast Cancer

HR+ Hormone Receptor-Positive

HER2- Human Epidermal Growth Factor Receptor 2-negative

HER2+ Human Epidermal growth factor Receptor 2 positivo.

mTNBC Metastatic Triple-Negative Breast Cancer



Sistema Qualità **ISO 9001**
Progettazione e Erogazione ECM

Nome e Cognome	Professione	Disciplina	Ente di Appartenenza / Libera Professione	Descrizione Attività Professionale / Formativa
Giampaolo Bianchini	Medicina e Chirurgia	Oncologia Medica	Università Vita Salute San Raffaele di Milano, IRCCS Ospedale San Raffaele, Milano	Professore Associato Oncologia Medica, Responsabile Dipartimento di Oncologia Medica
Carmen Criscitiello	Medicina e Chirurgia	Oncologia Medica	Humanitas University, IRCCS Istituto Clinico Humanitas di Rozzano; Milano	Professoressa Associata Oncologia Medica, Responsabile Unità Operativa di Oncologia Mammaria
Giuseppe Curigliano	Medicina e Chirurgia	Oncologia Medica	European Institute of Oncology, Milan; University of Milan; Milano	Head Division of Early Drug Development; Full Professor of Medical Oncology
Maria Vittoria Dieci	Medicina e Chirurgia	Oncologia Medica	Università di Padova, Istituto Oncologico Veneto IOV IRCCS; Padova	Professoressa Associata Oncologia Medica, Dirigente Medico I livello UOC Oncologia 2
Matteo Lambertini	Medicina e Chirurgia	Oncologia Medica	Università di Genova; IRCCS Ospedale Policlinico San Martino di Genova	Professore Associato; Dirigente Medico I livello Clinica di Oncologia Medica
Laura Marziali	Giurisprudenza, Psicologia	///	Associazione C'è Tempo OdV Montegiorgio; Fermo	Presidente dell'Associazione C'è Tempo OdV
Gabriella Pravettoni	Psicologia	Psicoterapia	Università Statale di Milano, Istituto Europeo di Oncologia; Milano	Docente di Psicologia Cognitiva e delle Decisioni, Direttore della Divisione di Psiconcologia
Leonardo Provenzano	Medicina e Chirurgia	Oncologia Medica	Fondazione IRCCS Istituto Nazionale dei Tumori; Milano	Dirigente Medico I livello Oncologia
Giancarlo Pruneri	Medicina e Chirurgia	Anatomia Patologica	Fondazione IRCCS Istituto Nazionale dei Tumori di Milano	Professore Ordinario Anatomia Patologica, Direttore Dipartimento Servizi e Diagnostica Avanzata e S.C. Anatomia Patologica
Dario Trapani	Medicina e Chirurgia	Oncologia Medica	Istituto Europeo di Oncologia IEO; Milano	Dirigente Medico Oncologo I livello Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative
Claudio Vernieri	Medicina e Chirurgia	Oncologia Medica	Università degli Studi di Milano; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Professore Associato di Oncologia Medica; Dirigente Medico I livello Breast Unit
Alberto Zambelli	Medicina e Chirurgia	Oncologia Medica	ASST Papa Giovanni XXIII, Bergamo	Direttore Struttura Complessa Oncologia